Antonella De Luca

Antonella De Luca

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonella De Luca has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anakinra restores cellular proteostasis by coupling mitochondrial redox balance to autophagy

    by Frank L. van de Veerdonk, Giorgia Renga, Marilena Pariano, Marina M. Bellet, Giuseppe Servillo, Francesca Fallarino, Antonella De Luca, Rossana G. Iannitti, Danilo Piobbico, Marco Gargaro, et al.

    Autophagy selectively degrades aggregation-prone misfolded proteins caused by defective cellular proteostasis. However, the complexity of autophagy may prevent the full appreciation of how its modulation could be used as a therapeutic strategy in disease management. Here, we define a molecular pathway through which recombinant IL-1 receptor antagonist (IL-1Ra, anakinra) affects cellular proteostasis independently from the IL-1 receptor (IL-1R1). Anakinra promoted H2O2-driven autophagy through a xenobiotic sensing pathway involving the aryl hydrocarbon receptor that, activated through the indoleamine 2,3-dioxygenase 1-kynurenine pathway, transcriptionally activated NADPH oxidase 4 independent of the IL-1R1. By coupling the mitochondrial redox balance to autophagy, anakinra improved the dysregulated proteostasis network in murine and human cystic fibrosis. We anticipate that anakinra may represent a therapeutic option in addition to its IL-1R1–dependent antiinflammatory properties by acting at the intersection of mitochondrial oxidative stress and autophagy with the capacity to restore conditions in which defective proteostasis leads to human disease.


  • Open Access

    Anakinra Activates Superoxide Dismutase 2 to Mitigate Inflammasome Activity

    by Marilena Pariano, Stefania Pieroni, Antonella De Luca, Rossana G. Iannitti, Monica Borghi, Matteo Puccetti, Stefano Giovagnoli, Giorgia Renga, Fiorella D’onofrio, Marina M. Bellet, et al.

    Inflammasomes are powerful cytosolic sensors of environmental stressors and are critical for triggering interleukin-1 (IL-1)-mediated inflammatory responses. However, dysregulation of inflammasome activation may lead to pathological conditions, and the identification of negative regulators for therapeutic purposes is increasingly being recognized. Anakinra, the recombinant form of the IL-1 receptor antagonist, proved effective by preventing the binding of IL-1 to its receptor, IL-1R1, thus restoring autophagy and dampening NLR family pyrin domain containing 3 (NLRP3) activity. As the generation of mitochondrial reactive oxidative species (ROS) is a critical upstream event in the activation of NLRP3, we investigated whether anakinra would regulate mitochondrial ROS production. By profiling the activation of transcription factors induced in murine alveolar macrophages, we found a mitochondrial antioxidative pathway induced by anakinra involving the manganese-dependent superoxide dismutase (MnSOD) or SOD2. Molecularly, anakinra promotes the binding of SOD2 with the deubiquitinase Ubiquitin Specific Peptidase 36 (USP36) and Constitutive photomorphogenesis 9 (COP9) signalosome, thus increasing SOD2 protein longevity. Functionally, anakinra and SOD2 protects mice from pulmonary oxidative inflammation and infection. On a preclinical level, anakinra upregulates SOD2 in murine models of chronic granulomatous disease (CGD) and cystic fibrosis (CF). These data suggest that protection from mitochondrial oxidative stress may represent an additional mechanism underlying the clinical benefit of anakinra and identifies SOD2 as a potential therapeutic target.


  • Open Access

    DISENTAGLING IMMUNITY AND TOLERANCE IN CANDIDIASIS

    by De Luca Antonella, Carvalho Agostinho, Iannitti Rossana, Giovannini Gloria, Bartolommei Lorenzo, Moretti Silvia, Massi Benedetti Cristina, Puccetti Matteo, Cunha Cristina, Romani Luigina

    The ability to tolerate Candida albicans, a component of human microbiota, implicates that host defense mechanisms of resistance and tolerance cooperate to limit fungal burden and inflammation at the different body sites. We have disentangled resistance and tolerance components of murine and human C. albicans mucosal infection and have introduced the challenging notion of a disease due to a defective tolerance mechanism. While some degree of inflammation is required for protection at mucosal tissues during the transitional response occurring between the rapid innate and slower adaptive responses, progressive inflammation worsens disease and ultimately prevents pathogen Resistance and tolerance mechanisms were both activated in murine intestinal and vaginal candidiasis through the contribution of innate and adaptive immune responses, involving distinct modules of immunity, IL-22 and Th1/Th17 cells for resistance and IL-10-producing regulatory T cells for tolerance., with a major contribution by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1). IDO1 was responsible for the production of tolerogenic kynurenines, such that replacement therapy with kynurenines restored immunoprotection to murine vaginal candidiasis. In humans, two functional genetic variants in IL22 and IDO1 genes were found to be associated with heightened resistance to recurrent vulvovaginal candidiasis, a disease of unknown origin, and they correlated with increased local expression of IL-22, IDO1 and kynurenines. Thus, IL-22 and IDO1 are crucial in balancing resistance with tolerance to Candida, their deficiencies are risk factors for mucosal infection resulting from transition from symbiont to pathobiont.